PVI
PRQR icon

Pura Vida Investments’s ProQR Therapeutics PRQR Stock Holding History

Pura Vida Investments’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-277,900
Closed -$252K – 258
2022
Q1 		$252K Buy
+277,900
New +$931K 0.01% 211

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Pura Vida Investments's PRQR Position: Q1 2019 in Review

Pura Vida Investments sold out of ProQR Therapeutics (PRQR) in Q1 2019, closing a stake of 76,827 shares — an estimated $1.21M sold.

Pura Vida Investments first reported a position in PRQR in Q2 2018 and held it in 3 quarters. The position peaked at $1.98M in Q2 2018. 56 funds tracked by Wall St. Rank hold PRQR as of Q1 2019.

  • Pura Vida Investments reported no remaining ProQR Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pura Vida Investments sold 76,827 ProQR Therapeutics shares in Q1 2019, an estimated $1.21M.
  • Pura Vida Investments first reported a position in ProQR Therapeutics in Q2 2018 and held it in 3 quarters.
  • Pura Vida Investments's ProQR Therapeutics position peaked at $1.98M in Q2 2018.
  • 56 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2019.

Based on Pura Vida Investments's 13F filing for Q1 2019, filed 14 May 2019.